FDA: potential risk of HIV and hepatitis transmission when insulin pens and...
An excerpt of FDA’s press release issued 19th March 2009: The U.S. Food and Drug Administration today issued an alert to health care professionals reminding them that single-patient insulin pens and...
View ArticleFDA video warning on metoclopramide and tardive dyskinesia
On February 2009 the FDA required all manufacturers of metoclopramide to include a boxed warning about the risks of developing tardive diskynesia after chronic use. Now the agency issues a patient...
View ArticleClik here to view.
FDA approves bevacizumab (Avastin) for glioblastoma multiforme
The FDA announced the approval of Avastin (bevacizumab) for the treatment of glioblastoma multiforme. Glioblastoma multiforme (GBM) is the most frequent and most aggressive type of primary brain...
View ArticleFDA video on erlotinib (Tarceva) adverse effects
The FDA published a new video warning on the adverse effects of erlotinib (Tarceva). Erlotinib is a chemotherapeutic agent; used to treat certain types of non-small cell lung cancer. It is also used...
View ArticleClik here to view.
FDA video: interaction of IV ceftriaxone with calcium-containing products
The FDA updated the full prescribing information of ceftriaxone (Rocephin and generics). This is an update to a previous ( september 2007) alert on the risk of interaction between ceftriaxone and...
View ArticleTNF blockers and lymphoma: FDA adds boxed warning
FDA required the manufacturers of TNF blockers (etanercept –Enbrel-, infliximab –Remicade-,adalimumab –HUMIRA-, among others) to make an update on existing Boxed Warning. This will include an alert to...
View ArticleGolimumab (Simponi) side effects: risk of serious fungal infections
Centocor Ortho Biotech and FDA reminded prescribers of the risk of serious fungal infections associated with TNF-α blockers, this includes the newer Simponi (golimumab). Simponi is a recently approved...
View Article
